Clinical Trials in Finland — Country Dashboard | 546 EU Studies

Filter these 546 trials by condition, phase, sponsor and more.

Open in Search →

546 Registered trials

232 Recruiting

249 Completed trials

178 Sponsors active

101 Research sites

Phase III

Phase II

Phase IV

Phase III: 287 Phase II/III: 31 Phase II: 94 Phase I/II: 21 Phase III/IV: 9 Phase IV: 66 Phase I: 10 Phase I (Other): 17 Phase I (FiH): 8 Other: 3

Oversight events in trials active here:

45 serious breaches 167 temporary halts 10 urgent safety measures 24 unexpected events 28 corrective measures across 80 trials

View oversight register →

Top conditions

Non-small cell lung cancer 10 Prostate cancer metastatic 8 Ovarian cancer 6 Obesity 5 Endometrial cancer 4 Multiple sclerosis 4 Bladder cancer 3 Non-small cell lung cancer metastatic 3 Breast cancer metastatic 3 Influenza 3 Respiratory syncytial virus infection 3 Ovarian cancer recurrent 3

Top sponsors

Merck Sharp & Dohme LLC 41 HUS-Yhtymae 30 Pfizer Inc. 25 Boehringer Ingelheim International GmbH 18 Turku University Hospital 17 Boehringer Ingelheim Espana S.A. 16 Glaxosmithkline Research & Development Limited 16 Bristol-Myers Squibb Services Unlimited Company 14 AstraZeneca AB 13 Novartis Pharma AG 13 Bayer AG 12 Pirkanmaan hyvinvointialue 12

Cities with most trials

All 30 cities →

All trials — page 18

546 total

A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or … Ended

2023-505478-14-00 Phase III Psoriatic Arthritis AbbVie Deutschland GmbH & Co. KG
TALAPRO 2: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT… Ended

2023-509087-20-00 Phase III Metastatic Castration-resistant Prostate Cancer Pfizer Inc.
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Phase III Acute myeloid leukemia Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended

2023-507906-15-00 Phase III Relapsing multiple sclerosis (RMS) Novartis Pharma AG
Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma… Ended

2022-502937-24-00 Phase III Atopic Dermatitis Abbvie Deutschland GmbH & Co. KG
A Phase 3 trial of BCG with or without pembrolizumab for High Risk Non Muscle Invasive Bladder Cancer Ended

2022-501817-29-00 Phase III High Risk Non-muscle invasive bladder cancer Merck Sharp & Dohme LLC
The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended

2024-510605-28-00 Phase III Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer Tesaro Inc.
A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM… Ended

2024-517417-32-00 Phase II CHRONIC MYELOID LEUKEMIA St. Olavs Hospital HF
Dual antiplatelet therapy with ticagrelor and acetylsalicylic acid (ASA) vs. ASA only after isolated coronary artery bypass grafting in pati… Ended

2023-508551-40-00 Phase IV Coronary artery multi-vessel disease and left main stenosis Vaestra Goetalandsregionen
A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma Ended

2024-510913-13-00 Phase II/III Previously Untreated Metastatic or Unresectable Melanoma Bristol-Myers Squibb Services Unlimited Company
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended

2023-504802-12-00 Phase I (FiH) Lymphoma of B-cell origin Genmab A/S
International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease … Ended

2024-513070-21-00 Phase II Relapsed Acute Lymphoblastic Leukemia (ALL) Charite Universitaetsmedizin Berlin KöR
ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma Ended

2024-514275-18-00 Phase II/III Mantle Cell Lymphoma (MCL) Region Skane; University Hospitals Plymouth NHS Trust
International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended

2024-515499-12-00 Phase III Acute lymphoblastic leukemia Universita Degli Studi Di Milano Bicocca
Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; P… Ended

2023-510159-53-01 Phase II peritoneal dissemination in stomach cancer patients Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
DupuytrEn Treatment EffeCtiveness Trial (DETECT) Ended

2024-515110-40-00 Phase III Dupuytren's contracture Pirkanmaan hyvinvointialue
B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and… Ended

2023-505509-18-00 Phase III mature aggressive B-cell lymphoma and leukemia in children a… Universitaetsklinikum Muenster AöR
A Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent … Ended

2023-505625-14-00 Phase I (FiH) Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL) F. Hoffmann-La Roche AG
Long Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis. Ended

2023-505699-31-00 Phase III Ulcerative Colitis AbbVie Deutschland GmbH & Co. KG
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended

2023-510298-33-00 Phase II Prostate Cancer Astellas Pharma Global Development Inc.
A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for … Ended

2024-517321-99-00 Phase II Myeloma multiplex HUS-Yhtymae
A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Al… Ended

2024-513962-20-00 Phase III Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency Grifols Therapeutics LLC
An international study to evaluate the safety and effectiveness of enzalutamide plus leuprolide, enzalutamide alone, and leuprolide alone in… Ended

2024-513521-23-00 Phase III Prostate Cancer Medivation Inc.
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage… Ended

2023-509136-25-00 Phase III Stage III melanoma (AJCC R0) with histologically confirmed c… Merck Sharp & Dohme LLC

Showing 409–432 of 546 trials

← All countries